A randomized trial tested if adding sacubitril/valsartan (ARNI) to a standard heart procedure (RFCA) would help patients with nonparoxysmal atrial fibrillation and high blood pressure. The study included 240 patients and followed them for 15 months after a 3-month healing period.
Patients who received ARNI plus the procedure were more likely to stay in normal heart rhythm compared to those who only had the procedure. About 80% of the ARNI group succeeded, versus about 69% of the control group. This represents about a 30% lower chance of rhythm problems.
The ARNI group also saw a smaller left atrial size and lower NT-proBNP levels, which are signs of better heart health. Patients with weaker heart function or specific heart tissue areas benefited even more, with success rates over 90% versus about 60%.
The study did not report on side effects or safety issues. It was limited to patients with high blood pressure who had a specific heart procedure, so results may not apply to everyone.
This research suggests that ARNI can be a helpful add-on treatment for certain patients after a heart procedure, improving their chances of staying in normal rhythm and overall heart health.